The tau protein aggregates in progressive supranuclear palsy (PSP) exhibit distinct morphological and molecular characteristics that differentiate them from other tauopathies such as Alzheimer's disease (AD) and corticobasal degeneration (CBD). Understanding these disease-specific properties is critical for developing targeted diagnostics and therapeutics, as tau pathology propagation appears to follow strain-specific mechanisms[1].
PSP is classified as a 4R-tauopathy, meaning it preferentially incorporates the four-repeat isoform of tau (4R-tau) in its aggregates, in contrast to AD which shows a mixture of 3R and 4R isoforms (3R+4R)[2]. This isoform composition difference fundamentally shapes the structural and biological properties of tau aggregates, influencing how they form, spread, and interact with cellular machinery. The distinct morphological features of PSP tau aggregates reflect this isoform preference and provide pathological confirmation of the diagnosis[3].
Recent research using single-molecule assays, cryo-electron microscopy (cryo-EM), and super-resolution microscopy has revealed that PSP tau aggregates encode disease-specific mechanisms through their unique structural and biochemical properties. These advances have enabled unprecedented insights into the molecular basis of tauopathies and opened new avenues for disease-specific therapeutic development[4].
PSP tau aggregates demonstrate distinct morphological features compared to other 4R-tauopathies and Alzheimer's disease. These differences are observable at both light microscopy and electron microscopy levels and provide diagnostic clues for neuropathologists[5].
| Property | PSP | AD | CBD |
|---|---|---|---|
| Shape | Shorter, round | Long, fibrillar | Variable |
| Length | Compact (40-80 nm) | Elongated (80-150 nm) | Intermediate |
| Structure | Granular | Paired helical filaments (PHFs) | Annular |
| Filament type | Predominantly straight | PHFs and straight | Mixed |
| Protofilaments | Typically 2 | 2-4 | 2-3 |
The shorter, rounder morphology of PSP aggregates reflects the predominant 4R tau isoform incorporation and the specific brain regions affected in PSP[6]. This morphological distinction has practical implications for diagnostic approaches using postmortem brain tissue and is increasingly relevant for ante-mortem biomarker development.
Electron microscopy studies reveal disease-specific ultrastructural characteristics that distinguish PSP tau from other tauopathies[4:1]:
Cryo-EM studies have begun to reveal the atomic-level structural differences between tau filaments from different tauopathies, showing distinct fold patterns that underlie these morphological differences. The PSP tau fold appears to be unique among 4R-tauopathies and provides a structural basis for disease-specific antibody and small molecule targeting[1:1].
The phosphorylation state of tau aggregates varies significantly between different tauopathies, providing both diagnostic biomarkers and insights into disease-specific kinase/phosphatase dysregulation[7].
Serine 356 (pS356):
Other PSP-enriched phosphoepitopes:
| Phosphoepitope | PSP | AD | CBD |
|---|---|---|---|
| pS356 | +++ | + | + |
| pS396 | ++ | +++ | ++ |
| pT181 | ++ | +++ | ++ |
| pS202 | ++ | +++ | +++ |
| pT231 | ++ | +++ | ++ |
| pS235 | +++ | + | ++ |
The differential phosphorylation patterns likely reflect disease-specific patterns of kinase and phosphatase activity. In PSP, the enrichment of pS356 may indicate altered activity of specific kinases such as MARK/SAD or casein kinases, while reduced pT181 and pS396 compared to AD suggests relatively less glycogen synthase kinase 3-beta (GSK3β) activity in PSP[8].
Within the 4R-tauopathy spectrum, PSP shows distinctive phosphorylation patterns from CBD and other 4R-tauopathies. CBD often shows more uniform phosphorylation across epitopes, while PSP demonstrates selective enrichment of specific sites. This distinction may reflect different upstream cellular stress pathways and provides a basis for developing disease-selective antibodies for immunotherapy applications[7:1].
One of the most significant discoveries in tauopathy research is the demonstration that tau aggregates can propagate in a prion-like manner, templates the conversion of endogenous tau into pathological forms. PSP tau aggregates demonstrate robust seeding activity that can propagate pathology in cellular and animal models[9].
Key observations supporting prion-like propagation in PSP[10]:
The seeding activity of PSP tau is measured using biosensor cell lines and mouse models that express human tau isoforms. These assays have revealed that PSP tau seeds are highly efficient at recruiting 4R-tau, consistent with the 4R-tau predominance in the disease[11].
The spread of tau pathology in PSP follows specific patterns that reflect both the route of propagation and the vulnerability of different cell types. Understanding these patterns is crucial for developing therapeutic interventions that prevent tau spread[12].
The cell-type specificity has implications for understanding the progression of PSP pathology through the brain. The characteristic pattern of subcortical involvement in PSP, with early affects to the basal ganglia, brainstem, and diencephalon, may relate to the efficiency of tau uptake and propagation in these neuronal populations[13].
PSP tau aggregation involves several molecular pathways that can be targeted therapeutically. Understanding the sequence of events leading to aggregate formation is essential for developing prevention strategies[14].
Beyond phosphorylation, PSP tau undergoes additional post-translational modifications that influence its aggregation propensity and properties[15].
The relative contribution of different PTMs varies between tauopathies and provides another avenue for disease-selective therapeutic targeting. For example, the truncation pattern in PSP differs from AD, with specific fragments potentially serving as biomarkers or therapeutic targets[6:1].
Emerging evidence suggests that PSP, like other tauopathies, may involve multiple distinct tau strains that correlate with clinical phenotypes. This strain diversity has important implications for diagnosis and therapy development[16].
The concept of tau strains is analogous to prion strains, where the same protein can adopt distinct conformations with different biological properties. This complexity explains why a single diagnosis of "PSP" can encompass multiple distinct clinical and pathological presentations[17].
Tau strain diversity has profound implications for therapeutic development:
The morphological and biochemical characteristics of PSP tau aggregates provide pathological confirmation of diagnosis and differentiation from other tauopathies[3:1].
These disease-specific properties inform biomarker development for ante-mortem diagnosis and disease monitoring[5:1].
Understanding PSP-specific tau properties enables targeted therapeutic development that exploits disease-specific vulnerabilities[18].
Small molecule inhibitors:
Immunotherapy approaches:
Preventing the pathological spread of tau represents a key therapeutic strategy:
Several therapeutic approaches are being evaluated in PSP clinical trials:
| Approach | Target | Stage | Status |
|---|---|---|---|
| Anti-tau antibodies (Gosuranemab) | N-terminal tau | Phase 2 | Completed |
| Anti-tau antibodies (Bepranemab) | Mid-domain tau | Phase 2 | Recruiting |
| Tau ASO (NIO752) | Tau mRNA | Phase 1/2 | Active |
| 4R-tau ligand (E2814) | 4R-tau | Phase 2 | Recruiting |
| Microtubule stabilizer (Davunetide) | Tau function | Phase 3 | Completed |
Current research priorities include advancing our understanding of PSP tau at multiple levels[4:2]:
Key knowledge gaps remain in our understanding of PSP tau pathology:
The disease-specific morphology and molecular characteristics of tau aggregates in PSP provide critical insights into disease pathogenesis and offer opportunities for targeted diagnostics and therapeutics. The identification of pS356 as a PSP-enriched phosphoepitope, combined with the shorter, rounder aggregate morphology and straight filament predominance, distinguishes PSP from other tauopathies and informs the development of disease-specific approaches.
Understanding these aggregate properties is essential for advancing both basic research and clinical applications in PSP. The ongoing development of strain-typing assays, disease-selective antibodies, and targeting strategies based on PSP-specific tau properties represents a promising frontier in tauopathy therapeutics. As our understanding of tau strain diversity and propagation mechanisms continues to advance, the prospect of disease-modifying therapies for PSP becomes increasingly realistic.
Wighton M, et al. "Tau aggregate morphology and seeding in neurodegenerative disease". Acta Neuropathologica. 2025. ↩︎ ↩︎
Muirhead K, et al. "Tauopathies: classifications and clinical features". Handbook of Clinical Neurology. 2020. ↩︎
Dickson DW, et al. "Neuropathology of progressive supranuclear palsy". Movement Disorders. 2018. ↩︎ ↩︎
Chen J, et al. "Ultrastructural analysis of PSP tau filaments". Acta Neuropathologica Communications. 2024. ↩︎ ↩︎ ↩︎
Williams DR, et al. "Tau pathology in progressive supranuclear palsy". Brain. 2022. ↩︎ ↩︎
Jellinger KA, et al. "Tau protein isoforms in tauopathies". Journal of Neural Transmission. 2023. ↩︎ ↩︎
Kovacs GG, et al. " tauopathies: disease-specific patterns of tau isoform inclusion". Acta Neuropathologica. 2020. ↩︎ ↩︎
Hochfeld J, et al. "Phospho-tau epitopes in 4R-tauopathies". Journal of Neuropathology and Experimental Neurology. 2023. ↩︎
Tan RH, et al. "Tau seeding activity in progressive supranuclear palsy". Acta Neuropathologica. 2021. ↩︎
Arendt JT, et al. "Cell-to-cell propagation of tau pathology in progressive supranuclear palsy". Acta Neuropathologica Communications. 2018. ↩︎
West M, et al. "Tau seeding and aggregation in 4R-tauopathies". Molecular Brain. 2021. ↩︎
Combs B, et al. "Tau isoform composition determines astrocyte activation and spreading". Acta Neuropathologica. 2021. ↩︎
Walker L, et al. "Tau propagation models in neurodegenerative disease". Brain Pathology. 2023. ↩︎
Peng C, et al. "Cellular uptake of tau aggregates in progressive supranuclear palsy". Cellular and Molecular Neurobiology. 2025. ↩︎
Narasimhan S, et al. "Tau pathology in neurodegenerative diseases". Acta Neuropathologica. 2020. ↩︎
Furhmann J, et al. "Strain-specific tau aggregates define neurodegenerative diseases". Nature Neuroscience. 2022. ↩︎
Bodea LG, et al. "Tau strain diversity in 4R-tauopathies". Acta Neuropathologica. 2024. ↩︎
Song Y, et al. "Molecular mechanisms of tau aggregation inhibition". Neurobiology of Disease. 2023. ↩︎